DLI Del Laboratories

Del Laboratories Confirms That Kelso and Company Will Contribute Additional Funds to DLI Holding Corporation UNIONDALE, N.Y., Dec. 7 /PRNewswire-FirstCall/ -- Del Laboratories, Inc. (AMEX:DLI) today confirmed that Kelso & Company will contribute an additional $30 million to DLI Holding Corp., the entity that will acquire Del Laboratories, Inc. for $35 per share in cash. Earlier today, Del announced that, by mutual agreement, Church & Dwight, Co., Inc. (NYSE:CHD), will not be a participant in DLI Holding. Kelso's additional $30,000,000 contribution will replace the equity contribution previously committed by Church & Dwight. Del Laboratories, Inc., markets and manufactures leading cosmetics and over the counter pharmaceuticals. The Company's two flagship brands, Sally Hansen and Orajel, are both leaders in their respective categories, and continue to build revenues and market share. Certain statements in this press release may constitute "forward-looking statements" under the federal securities laws. Forward-looking statements contain information that is subject to certain risks, uncertainties, trends and other factors that could cause actual results to be materially different from any future results implied by such forward-looking statements. Factors that might cause such a difference include, but are not limited to: delays in introducing new products or failure of consumers to accept new products; actions by competitors which may result in mergers, technology improvement or new product introductions; the dependence on certain national chain drug stores, food stores and mass merchandiser relationships due to the concentration of sales generated by such chains; changes in fashion-oriented color cosmetic trends; the effect on sales of lower retailer inventory targets; the effect on sales of political and/or economic conditions; the Company's estimates of costs and benefits, cash flow from operations and capital expenditures; interest rate or foreign exchange rate changes affecting the Company and its market sensitive financial instruments including the Company's qualitative and quantitative estimates as to market risk sensitive instruments; changes in product mix to products which are less profitable; shipment delays; depletion of inventory and increased production costs resulting from disruptions of operations at any of our manufacturing or distribution facilities; foreign currency fluctuations affecting our results of operations and the value of our foreign assets and liabilities; the relative prices at which we sell our products and our foreign competitors sell their products in the same market; our operating and manufacturing costs outside of the United States; changes in the laws, regulations and policies, including changes in accounting standards, that effect, or will effect, us in the United States and/or abroad; and trends in the general economy. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved. Without limitation, use of the following words is intended to identify forward-looking statements: "may," "will," "should," "expect," "anticipate," "estimate," "intend," "plan," or "continue" or the negative thereof or other variations thereon. For further information on factors which could impact the Company and the statements contained herein, please refer to the Company's filings with the Securities and Exchange Commission, including without limitation the Company's Annual Report on Form 10-K and the "Management's Discussion and Analysis of Financial Condition and Results of Operations" contained or incorporated by reference therein and quarterly reports on Form 10-Q. Filings with the Securities and Exchange Commission are available on the Company's website at http://www.dellabs.com/. CONTACT: Enzo J. Vialardi Executive Vice President and Chief Financial Officer Del Laboratories, Inc. 178 EAB Plaza P.O. Box 9357 Uniondale, New York 11553-9357 (516) 844-2050 DATASOURCE: Del Laboratories, Inc. CONTACT: Enzo J. Vialardi, Executive Vice President and Chief Financial Officer of Del Laboratories, Inc., +1-516-844-2050 Web Site: http://www.dellabs.com/

Copyright